Table 2 Levels of antibodies at the first episode of clinical malaria (acute) and one month later (convalescence) in relation to the levels of antibodies at the immediately preceding cross-sectional visit (pre-acute) in the three study groups

IgG

MSP-1₁₉

0.47

0.73

1.56

1.20; 2.02

3.02

6.39

4.86; 8.40

< 0.0001

AMA-1

0.56

0.50

0.88

0.71; 1.09

1.01

1.80

1.44; 2.25

< 0.0001

EBA-175

0.53

0.41

0.77

0.65; 0.91

0.56

1.04

0.87; 1.24

< 0.0013

VSA

17.46

8.60

0.49

0.27; 0.91

11.58

0.64

0.39; 1.06

< 0.0398

IgM

MSP-1₁₉

0.45

0.68

1.50

1.29; 1.73

0.67

1.47

1.26; 1.72

< 0.0001

AMA-1

0.39

0.44

1.11

0.99; 1.26

0.48

1.23

1.08; 1.39

< 0.0083

EBA-175

0.42

0.49

1.14

1.03; 1.26

0.51

1.18

1.06; 1.31

< 0.0046

IgG1

MSP-1₁₉

0.30

0.47

1.54

1.16; 2.04

2.32

7.48

5.54; 10.1

< 0.0001

AMA-1

0.37

0.31

0.82

0.65; 1.04

0.64

1.73

1.35; 2.22

< 0.0001

EBA-175

0.31

0.21

0.69

0.59; 0.81

0.27

0.87

0.74; 1.03

< 0.0001

IgG3

MSP-1₁₉

0.11

0.15

1.30

0.99; 1.70

0.49

4.36

3.28; 5.78

< 0.0001

AMA-1

0.14

0.13

0.93

0.77; 1.12

0.29

2.04

1.66; 2.50

< 0.0001

EBA-175

0.11

0.07

0.61

0.52; 0.72

0.09

0.80

0.67; 0.95

< 0.0001